Cargando…
Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus associated with coronavirus disease (COVID-19). At the time of the study, little data on the level of exposure of the population in Koutiala district in Mali to SARS-CoV-2 was available. Although blood donors are not represent...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022217/ https://www.ncbi.nlm.nih.gov/pubmed/36962828 http://dx.doi.org/10.1371/journal.pgph.0001316 |
_version_ | 1784908681628876800 |
---|---|
author | Temessadouno, Fara Wagbo Ndong, Jean Gilbert Gignoux, Etienne Coppieters, Yves Ba, Alhassane Sidibe, Youssouf Diam Daou, Aminata Malou, Nada Compaore, Idrissa Fane, Tidiani Simons, Erica Luquero, Francisco Mills, Clair Vuti, Komla Mawunya Nkokolo massamba, Marie Hortense Guiramand, Sonia |
author_facet | Temessadouno, Fara Wagbo Ndong, Jean Gilbert Gignoux, Etienne Coppieters, Yves Ba, Alhassane Sidibe, Youssouf Diam Daou, Aminata Malou, Nada Compaore, Idrissa Fane, Tidiani Simons, Erica Luquero, Francisco Mills, Clair Vuti, Komla Mawunya Nkokolo massamba, Marie Hortense Guiramand, Sonia |
author_sort | Temessadouno, Fara Wagbo |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus associated with coronavirus disease (COVID-19). At the time of the study, little data on the level of exposure of the population in Koutiala district in Mali to SARS-CoV-2 was available. Although blood donors are not representative of the general population, a COVID-19 seroprevalence estimate in this population was intended to assess the extent of community transmission, serve as a health alert system, and help guide the public health response. We measured seroprevalence of anti-SARS-CoV-2 antibodies using NG-Biotech SARS-Cov-2 RDT and ECLIA test between January and June 2020. This is a cross-sectional study of volunteer blood donors aged 18 to 60 years, independent of any previous COVID-19 disease. A stratified analysis of seroprevalence by month of sample collection and a comparison of the results of the NG-Biotech SARS-Cov-2 RDT with those of the ECLIA test was performed. The overall prevalence of antibodies to SARS-Cov-2 virus assessed by the NG-Biotech SARS-Cov-2 RDT was 24.6% (95% CI 21.8–27.4) and by the ECLIA test was 70.2 (95% CI 64.9–75.5). Both estimates remained relatively stable over the study period. We observed SARS-CoV-2 exposure much higher than indicated by case-based surveillance. The national surveillance system, as it was, was not able to detect variations in incidence, and as such, we do not recommend it as an alert system. However, the discrepancy between the results of the rapid test and the ECLIA test shows that further research is required to assess the validity of these test before a more solid conclusion can be drawn it their use in surveillance. |
format | Online Article Text |
id | pubmed-10022217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-100222172023-03-17 Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali Temessadouno, Fara Wagbo Ndong, Jean Gilbert Gignoux, Etienne Coppieters, Yves Ba, Alhassane Sidibe, Youssouf Diam Daou, Aminata Malou, Nada Compaore, Idrissa Fane, Tidiani Simons, Erica Luquero, Francisco Mills, Clair Vuti, Komla Mawunya Nkokolo massamba, Marie Hortense Guiramand, Sonia PLOS Glob Public Health Research Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus associated with coronavirus disease (COVID-19). At the time of the study, little data on the level of exposure of the population in Koutiala district in Mali to SARS-CoV-2 was available. Although blood donors are not representative of the general population, a COVID-19 seroprevalence estimate in this population was intended to assess the extent of community transmission, serve as a health alert system, and help guide the public health response. We measured seroprevalence of anti-SARS-CoV-2 antibodies using NG-Biotech SARS-Cov-2 RDT and ECLIA test between January and June 2020. This is a cross-sectional study of volunteer blood donors aged 18 to 60 years, independent of any previous COVID-19 disease. A stratified analysis of seroprevalence by month of sample collection and a comparison of the results of the NG-Biotech SARS-Cov-2 RDT with those of the ECLIA test was performed. The overall prevalence of antibodies to SARS-Cov-2 virus assessed by the NG-Biotech SARS-Cov-2 RDT was 24.6% (95% CI 21.8–27.4) and by the ECLIA test was 70.2 (95% CI 64.9–75.5). Both estimates remained relatively stable over the study period. We observed SARS-CoV-2 exposure much higher than indicated by case-based surveillance. The national surveillance system, as it was, was not able to detect variations in incidence, and as such, we do not recommend it as an alert system. However, the discrepancy between the results of the rapid test and the ECLIA test shows that further research is required to assess the validity of these test before a more solid conclusion can be drawn it their use in surveillance. Public Library of Science 2023-01-05 /pmc/articles/PMC10022217/ /pubmed/36962828 http://dx.doi.org/10.1371/journal.pgph.0001316 Text en © 2023 Temessadouno et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Temessadouno, Fara Wagbo Ndong, Jean Gilbert Gignoux, Etienne Coppieters, Yves Ba, Alhassane Sidibe, Youssouf Diam Daou, Aminata Malou, Nada Compaore, Idrissa Fane, Tidiani Simons, Erica Luquero, Francisco Mills, Clair Vuti, Komla Mawunya Nkokolo massamba, Marie Hortense Guiramand, Sonia Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali |
title | Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali |
title_full | Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali |
title_fullStr | Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali |
title_full_unstemmed | Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali |
title_short | Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali |
title_sort | seroprevalence of anti-sars-cov-2 antibodies among blood donors from december 2020 to june 2021 in koutiala district, mali |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022217/ https://www.ncbi.nlm.nih.gov/pubmed/36962828 http://dx.doi.org/10.1371/journal.pgph.0001316 |
work_keys_str_mv | AT temessadounofarawagbo seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT ndongjeangilbert seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT gignouxetienne seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT coppietersyves seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT baalhassane seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT sidibeyoussoufdiam seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT daouaminata seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT malounada seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT compaoreidrissa seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT fanetidiani seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT simonserica seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT luquerofrancisco seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT millsclair seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT vutikomlamawunya seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT nkokolomassambamariehortense seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali AT guiramandsonia seroprevalenceofantisarscov2antibodiesamongblooddonorsfromdecember2020tojune2021inkoutialadistrictmali |